Railcare avslutade året med ett kvartal där svaghet inom Entreprenad vägdes upp av en förbättring in...
* Orders +11% vs cons, sales +14% and adj. EBIT +32% * Europe is leading the way (+90% y-o-y), high ...
* NOI 2% y-o-y, 2.4% vs ABGSCe, 1.5% vs cons. * Value changes of -0.
Etteplan's Q4 results came slightly below expectations, but showed progress from last year.
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat o...
Following last year’s breakthrough integration into India’s payment ecosystem, Crunchfish enters 202...
Profitability was mainly in line with our expectations and didn’t offer surprises.
Vaisala’s Q4 revenue and EBITA came in close to estimates.
Marimekko's fourth quarter revenue missed our estimates slightly, weighed down by wholesale weakness...
SRV’s Q4 results came in quite as expected. We expect slow but steady progress in 2026, with all eye...
Finnair’s Q4 earnings reached a record high especially due to efficient operations.
Redeye comments on Lime’s Q4 report, showing 10% organic ARR growth, slightly below our expectations...
As anticipated, Genovis’ year-end report showcased robust top-line momentum, with sharp sales growth...
Redeye's immediate impression of Stille's year-end report 2025 is positive.
* Sales 2% and adj. EBIT -31% vs. ABGSCe * Order intake SEK 251m, above expectations * Likely negati...
* Sales of SEK 61m (-5% vs. ABGSCe), a 3% y-o-y growth * ARR continues to grow, up 5%, and defence u...
Atria reported Q4 adjusted EBIT of EUR 14.0m, 3% below LSEG Data & Analytics consensus.
Redeye provides its initial take on Acarix’s Q4 report, which beat our topline estimates, while cost...
Redeye provides its initial take on Ferroamp’s Q4 numbers, which presented strong sales growth and s...
Tradedoubler's Q4 report was impacted by a significant revaluation of the KaHa earnout liability, wh...
